目次

Table of Content

1. Introduction To TIGIT Inhibitors
1.1 Overview
1.2 Mechanistic Insights Into TIGIT Inhibitor Function
1.3 Clinical Strategies For Targeting TIGIT

2. Global TIGIT Inhibitors Clinical Trials Overview
2.1 By Company
2.2 By Country
2.3 By Indication
2.4 By Phase

3. Global TIGIT Inhibitors Clinical Pipeline By Company, Indication and Phase
3.1 Research
3.2 Preclinical
3.3 Phase I
3.4 Phase I/II
3.5 Phase II
3.6 Phase III

4. Global TIGIT Inhibitors Market Outlook
4.1 Current Clinical and Market Trends
4.2 Future Market Opportunities

5. TIGIT Inhibitors Market Trends by Indication
5.1 Cancer
5.2 Autoimmune and Inflammatory Disorders
5.3 Microbial Infections

6. TIGIT Inhibitors Market Trends By Region
6.1 US
6.2 China
6.3 South Korea
6.4 Australia
6.5 Europe

7. Integrating TIGIT Inhibition With Other Therapeutic Modalities

8. Dual Checkpoint Blockade - TIGIT With PD-1/PD-L1

9. Global TIGIT Inhibitors Market Dynamics
9.1 Market Drivers and Opportunities
9.2 Commercialization Challenges and Solutions

10. Competitive Landscape
10.1 Akeso Biopharma
10.2 AstraZeneca
10.3 BeOne Medicines
10.4 Bio-Thera Solutions
10.5 BioNTech
10.6 Compugen
10.7 FutureGen Biopharmaceutical
10.8 Merck and Co / MSD
10.9 Nanjing Sanhome Pharmaceutical
10.10 OriCell Therapeutics
10.11 Phio Pharmaceuticals
10.12 Roche
10.13 Shanghai Henlius Biotech
10.14 Shanghai Junshi Biosciences
10.15 Simcere Pharmaceutical Group

List of Figures & Tables
Figure 1-1: TIGIT/DNAX Accessory Molecule-1 Pathway
Figure 1-2: TIGIT Inhibitors - Proposed Mechanism of Action
Figure 1-3: TIGIT Inhibitor - Mechanism Of Action
Figure 1-4: Monoclonal Antibody - Binding Efficacy
Figure 1-5: Bispecific Antibodies - Binding Efficacy
Figure 1-6: Small Molecule Drugs - Advantages
Figure 2-1: Global - TIGIT Inhibitors Clinical Trials by Company (Number of Drugs), 2026
Figure 2-2: Global - TIGIT Inhibitors Clinical Trials by Country (Number of Drugs), 2026
Figure 2-3: Global - TIGIT Inhibitors Clinical Trials by Indication (Number of Drugs), 2026
Figure 2-4: Global - TIGIT Inhibitors Clinical Trials by Phase (Number of Drugs), 2026
Figure 4-1: Global TIGIT Inhibitors Market - Future Market Opportunities
Figure 5-1: TIGIT - Impact On Tumor Microenvironment
Figure 5-2: TIGIT In Cancer Immune Escape
Figure 5-3: PACIFIC-8 Phase 3 (NCT05211895) Study - Initiation and Completion Year
Figure 5-4: STAR-221 Phase 3 (NCT05568095) Study - Initiation and Completion Year
Figure 5-5: STAR-121 Phase 3 (NCT05502237) Study - Initiation and Completion Year
Figure 5-6: Rilvegostomig - Ongoing Phase 3 Clinical Trials
Figure 5-7: TIGIT Mechanisms In Tregs
Figure 5-8: Microbial Infections - TIGIT Signaling and Immune Suppression
Figure 5-9: Microbial Infections - Therapeutic Targeting Of TIGIT
Figure 7-1: TIGIT Therapy Combinations
Figure 7-2: TIGIT Inhibitor Combination Trials
Figure 9-1: Global TIGIT Inhibitors Market - Drivers and Opportunities
Figure 9-2: Global TIGIT Inhibitors Market - Commercialization Challenges and Solutions
Table 5-1: TIGIT Expression On Immune Cells
Table 5-2: TIGIT Expression and Regulation and Tregs and Other Cells
Table 5-3: TIGIT Ligands and Functional Mechanisms
Table 5-4: TIGIT In Autoimmune Diseases
Table 5-5: TIGIT Function In Immune Cells During Infection